GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt
· Delayed Price · Currency is EGP 67.17
-0.81 (-1.19%)
At close: Apr 28, 2026
GlaxoSmithKline S.A.E Balance Sheet
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 479.69 | 75.47 | 829.34 | 585.85 | 73.57 | Upgrade
|
| Cash & Short-Term Investments | 479.69 | 75.47 | 829.34 | 585.85 | 73.57 | Upgrade
|
| Cash Growth | 535.59% | -90.90% | 41.56% | 696.36% | 232.01% | Upgrade
|
| Accounts Receivable | 768.37 | 803.28 | 685.96 | 424.68 | 253.94 | Upgrade
|
| Other Receivables | 3 | 50.34 | 23.89 | 318.64 | 408.81 | Upgrade
|
| Receivables | 1,693 | 1,844 | 1,176 | 1,165 | 830.42 | Upgrade
|
| Inventory | 1,419 | 945.21 | 695.27 | 485.89 | 500.45 | Upgrade
|
| Prepaid Expenses | - | - | - | - | 17.58 | Upgrade
|
| Other Current Assets | - | - | 164.7 | 216.65 | 126.47 | Upgrade
|
| Total Current Assets | 3,592 | 2,865 | 2,866 | 2,454 | 1,548 | Upgrade
|
| Property, Plant & Equipment | 756.84 | 641.17 | 572.14 | 548.11 | 540.21 | Upgrade
|
| Long-Term Investments | 42.63 | 7.34 | 6.34 | 24.45 | 12.3 | Upgrade
|
| Goodwill | - | - | - | 137.65 | 238.65 | Upgrade
|
| Long-Term Deferred Tax Assets | - | 23.33 | 17.43 | - | - | Upgrade
|
| Other Long-Term Assets | 109.97 | 115.83 | 96.48 | 21.33 | 85.09 | Upgrade
|
| Total Assets | 4,501 | 3,653 | 3,558 | 3,185 | 2,425 | Upgrade
|
| Accounts Payable | 1,023 | 486.93 | 524.53 | 176.8 | 104.54 | Upgrade
|
| Accrued Expenses | 684.14 | 577.83 | 524.12 | 304.51 | 581.22 | Upgrade
|
| Short-Term Debt | - | - | - | - | 118.21 | Upgrade
|
| Current Portion of Leases | 43.79 | 38.28 | 28.39 | 17.48 | 29.52 | Upgrade
|
| Current Income Taxes Payable | 65.51 | 159.39 | 97.93 | 308.57 | 17.38 | Upgrade
|
| Other Current Liabilities | 394.88 | 313.45 | 348.98 | 585.89 | 161.22 | Upgrade
|
| Total Current Liabilities | 2,211 | 1,576 | 1,524 | 1,393 | 1,012 | Upgrade
|
| Long-Term Leases | 37.97 | 81.2 | 68.63 | 52.07 | 32.24 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 34.43 | - | - | 11.31 | 22.46 | Upgrade
|
| Total Liabilities | 2,284 | 1,657 | 1,593 | 1,457 | 1,067 | Upgrade
|
| Common Stock | 835.14 | 835.14 | 835.14 | 835.14 | 835.14 | Upgrade
|
| Retained Earnings | 1,382 | 1,160 | 1,130 | 892.71 | 522.24 | Upgrade
|
| Total Common Equity | 2,217 | 1,995 | 1,965 | 1,728 | 1,357 | Upgrade
|
| Minority Interest | 0.61 | 0.6 | 0.6 | 0.58 | 0.58 | Upgrade
|
| Shareholders' Equity | 2,217 | 1,996 | 1,965 | 1,728 | 1,358 | Upgrade
|
| Total Liabilities & Equity | 4,501 | 3,653 | 3,558 | 3,185 | 2,425 | Upgrade
|
| Total Debt | 81.76 | 119.48 | 97.03 | 69.55 | 179.97 | Upgrade
|
| Net Cash (Debt) | 397.93 | -44.01 | 732.32 | 516.3 | -106.41 | Upgrade
|
| Net Cash Growth | - | - | 41.84% | - | - | Upgrade
|
| Net Cash Per Share | 4.76 | -0.53 | 8.77 | 6.18 | -1.27 | Upgrade
|
| Filing Date Shares Outstanding | 83.51 | 83.51 | 83.51 | 83.51 | 83.51 | Upgrade
|
| Total Common Shares Outstanding | 83.51 | 83.51 | 83.51 | 83.51 | 83.51 | Upgrade
|
| Working Capital | 1,380 | 1,289 | 1,342 | 1,060 | 536.41 | Upgrade
|
| Book Value Per Share | 26.54 | 23.89 | 23.53 | 20.69 | 16.25 | Upgrade
|
| Tangible Book Value | 2,217 | 1,995 | 1,965 | 1,590 | 1,119 | Upgrade
|
| Tangible Book Value Per Share | 26.54 | 23.89 | 23.53 | 19.04 | 13.40 | Upgrade
|
| Land | 17.59 | 17.59 | 17.59 | 12.65 | 12.65 | Upgrade
|
| Buildings | 65.48 | 74.34 | 83.47 | 97.81 | 97.81 | Upgrade
|
| Machinery | 811.29 | 696.44 | 668.83 | 662.18 | 629.59 | Upgrade
|
| Construction In Progress | 197.12 | 152.54 | 108.51 | 88.86 | 98.67 | Upgrade
|
| Leasehold Improvements | 35.38 | 24.27 | 26.81 | 26.85 | 42.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.